
- Pharmaceutical Commerce - October 2009
IT vendor offers a package for compliance with DEA monitoring requirements
Suspicious Order Monitoring (SOMLink) tracks ordering history with statistical analysis of baseline activity
The Drug Enforcement Administration (DEA) turned their screws on several major wholesalers last year for failing to properly monitor “suspicious orders”—those that, by their frequency, size or source indicate that abuse of controlled substances might be going on. Under DEA rules (21 CFR Part 1301.74b), manufacturers and distributors must carry out some level of monitoring. For that purpose, SOMLink, from e-SupplyLink (Traverse City, MI), maintains a database of client ordering history, and then flags suspicious orders, which are supposed to be held up until a manual check is completed. The package includes a variety of statistical analytical tools to identify out-of-the ordinary ordering patterns, according to Ronald McCreery, sales manager.
The SOMLink package runs on a Windows operating system, and can be linked, via XML, to a client’s ERP system, warehouse management system (WMS) or EDI-based financial reporting systems, according ot the company. E-SupplyLInk has a decade’s experience as a developer of EDI transaction software, shipping-label generation and order fulfillment; its flagship product is called ComplyLink.
Articles in this issue
almost 16 years ago
Bristol-Myers Squibb, Roche Lead on Environmental Sustainability Scoringalmost 16 years ago
Comparative Effectiveness with the Gloves Offalmost 16 years ago
New effort on collaboration over product serializationabout 16 years ago
A small victory for Pharma in EU parallel trade warabout 16 years ago
Regenerative medicine coalition gets organizedabout 16 years ago
Flu Season Promises to Put a Spotlight on Vaccine Distributionabout 16 years ago
NACDS Annual Profile Tracks Declining Number of StoresNewsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.